Phase I Dose Escalation Trial of Efavirenz for Patients With Solid Tumours or Non-Hodgkin Lymphoma in Therapeutic Failure.
Phase of Trial: Phase I
Latest Information Update: 04 Oct 2017
Price : $35 *
At a glance
- Drugs Efavirenz (Primary)
- Indications Non-Hodgkin's lymphoma; Solid tumours
- Focus Adverse reactions
- Acronyms ESCALE
- 29 Sep 2017 Status changed from active, no longer recruiting to completed.
- 24 May 2016 Planned End Date changed from 1 Dec 2015 to 1 Dec 2016.
- 06 Jul 2013 New trial record